Chemomab Therapeutics (CMMB) EBITDA (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly EBITDA came in at $625.7 billion in Q4 2025, up 65.9% YoY from $377.2 billion in Q4 2024, and up 35920142.37% on a QoQ basis from $1.7 million in Q3 2025.
Chemomab Therapeutics (CMMB) EBITDA (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of EBITDA data on file, last reported at $625.7 billion in Q4 2025.
- Quarterly EBITDA rose 65.9% year-over-year to $625.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1002.9 billion (up 165.89% YoY) and the FY2025 annual result came in at $40.9 million, up 34.98% from the prior year.
- EBITDA rose to $625.7 billion in Q4 2025, from $1.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $625.7 billion in Q4 2025 to a low of -$5.1 million in Q1 2022.
- A 5-year average of $55.7 billion and a median of $5.4 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA plunged 199.53% — and 2024, when it soared 804319.98%.
- Tracing CMMB's EBITDA over 5 years: stood at $31.0 million in 2021, then surged by 59.57% to $49.5 million in 2022, then dropped by 5.19% to $46.9 million in 2023, then soared by 804319.98% to $377.2 billion in 2024, then soared by 65.9% to $625.7 billion in 2025.
- The last three EBITDA figures came in at $625.7 billion (Q4 2025), $1.7 million (Q3 2025), and $377.2 billion (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 625.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 625.73 Bn |
| Sep 30, 2025 | 1.74 Mn |
| Dec 31, 2024 | 377.18 Bn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 46.89 Mn |
| Sep 30, 2023 | 4.14 Mn |
| Jun 30, 2023 | 7.94 Mn |
| Mar 31, 2023 | 8.73 Mn |
| Dec 31, 2022 | 49.46 Mn |
| Sep 30, 2022 | 8.08 Mn |
| Jun 30, 2022 | 6.73 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | 30.99 Mn |
| Sep 30, 2021 | -2.97 Mn |
| Jun 30, 2021 | -2.77 Mn |
| Mar 31, 2021 | -1.70 Mn |
| Dec 31, 2020 | -6.14 Mn |
| Sep 30, 2020 | -2.45 Mn |